Verde Science, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRCI research report →
Price Chart
About the company
Verde Science, Inc. , a pharmaceutical research and development enterprise, is dedicated to advancing a diverse array of prescription medications derived from cannabinoids, intended for the treatment of numerous health conditions. The company, which initially operated as Rango Energy, Inc.
- CEO
- Harpreet Singh Sangha
- IPO
- 2009
- Employees
- 1
- HQ
- Dallas, TX, US
Get TickerSpark's AI analysis on VRCI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $477
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.12
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 401.28%
- ROIC
- 333.94%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,895,888
- Net Income
- $-2,612,479-227.3%
- EPS
- $-6.12-175.7%
- OCF Growth
- -143.3%
- FCF Growth
- -11.7%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -6.16
- RSI (14)
- 52
- Avg Volume
- 484.90K
No earnings-call transcripts are available for VRCI yet.
- Free Float
- 86.8%
- Shares Outstanding
- 23.87M
- Float Shares
- 20.72M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 26, 15 | Sangha Harpreet Singh | buy | 4,000,000 |
| Sep 30, 14 | Sangha Harpreet Singh | buy | 1,000,000 |
| Sep 30, 14 | Sangha Harpreet Singh | buy | 1,000,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VRCI coverage
Recent articles, reports, and earnings notes.
No research on VRCI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VRCI report →Verici Dx gains Olink Certified Service Provider status to expand proteomics offering
proactiveinvestors.co.uk · Aug 11
Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test
businesswire.com · Jun 24
Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
businesswire.com · May 19
Verici Dx rises after passing key US laboratory accreditation audit
proactiveinvestors.co.uk · Nov 12
Verici Dx climbs on 'preferred provider' deal with US healthcare network
proactiveinvestors.co.uk · Nov 6
Verici Dx shares jump 23% as transplant test rollout gathers pace
proactiveinvestors.co.uk · Oct 6
Verici Dx plans fresh funding round to boost US test rollout
proactiveinvestors.co.uk · Jun 11
Verici Dx soars as Tutivia tests are confirmed by Medicare
proactiveinvestors.co.uk · Apr 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.